by Dr Lloyd Matowe
The COVID-19 pandemic exposed a fundamental weakness in Africa’s pharmaceutical systems: when global supply chains fail, the continent faces acute shortages of medicines, raw materials, diagnostics and other essential health products. Border closures, export restrictions, manufacturing interruptions and transport constraints revealed the cost of excessive dependence on external suppliers. Recent disruptions to externally funded health programs reinforce the same lesson: systems built around volatile donor financing cannot provide lasting health security.
These shocks also create a clear opportunity to redesign how Africa governs, finances and supplies medicines. Resilience must extend beyond emergency stockpiles. It requires African ownership, regional cooperation, diversified supply, effective regulation, sustainable financing, local manufacturing and data-driven decision-making. The foundations already exist: the African Medicines Agency can deepen regulatory alignment, while ZAZIBONA and pooled procurement initiatives show how shared expertise and aggregated demand can accelerate access, improve affordability and strengthen supply security.
Africa should therefore move from fragmented national systems to an integrated continental market built on coordinated regulation, strategic pooled procurement, competitive regional production, professional supply-chain leadership and diversified investment. The ambition is not merely to endure the next crisis. It is to create a responsive pharmaceutical ecosystem that anticipates disruption, absorbs shocks and consistently delivers quality-assured medicines to every person who needs them.
Africa has the talent, markets and institutions to lead this transformation. What it needs now is sustained political commitment, disciplined investment and collective action—so resilience becomes a permanent capability, not a temporary response to crisis.